129 related articles for article (PubMed ID: 23052314)
21. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of the analytical specificity of the hybrid capture 2 test: data from the New Technologies for Cervical Cancer (NTCC) study.
Gillio-Tos A; De Marco L; Carozzi FM; Del Mistro A; Girlando S; Burroni E; Frayle-Salamanca H; Giorgi Rossi P; Pierotti P; Ronco G;
J Clin Microbiol; 2013 Sep; 51(9):2901-7. PubMed ID: 23804385
[TBL] [Abstract][Full Text] [Related]
23. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
[TBL] [Abstract][Full Text] [Related]
24. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
25. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
[TBL] [Abstract][Full Text] [Related]
26. Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.
Andersson E; Kärrberg C; Rådberg T; Blomqvist L; Zetterqvist BM; Ryd W; Lindh M; Horal P
J Clin Microbiol; 2011 Nov; 49(11):3794-9. PubMed ID: 21940473
[TBL] [Abstract][Full Text] [Related]
27. Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.
Clad A; Reuschenbach M; Weinschenk J; Grote R; Rahmsdorf J; Freudenberg N
J Clin Microbiol; 2011 Mar; 49(3):1071-6. PubMed ID: 21191046
[TBL] [Abstract][Full Text] [Related]
28. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women.
Ki EY; Lee YK; Lee A; Park JS
Yonsei Med J; 2018 Jul; 59(5):662-668. PubMed ID: 29869464
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer.
Marks MA; Castle PE; Schiffman M; Gravitt PE
J Clin Microbiol; 2012 Feb; 50(2):300-6. PubMed ID: 22162556
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
[TBL] [Abstract][Full Text] [Related]
32. Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia.
Oliveira A; Verdasca N; Pista Â
J Med Virol; 2013 Jul; 85(7):1235-41. PubMed ID: 23918542
[TBL] [Abstract][Full Text] [Related]
33. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy.
Einstein MH; Smith KM; Davis TE; Schmeler KM; Ferris DG; Savage AH; Gray JE; Stoler MH; Wright TC; Ferenczy A; Castle PE
J Clin Microbiol; 2014 Jun; 52(6):2089-95. PubMed ID: 24719440
[TBL] [Abstract][Full Text] [Related]
34. Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening.
Hesselink AT; Meijer CJ; Poljak M; Berkhof J; van Kemenade FJ; van der Salm ML; Bogaarts M; Snijders PJ; Heideman DA
J Clin Microbiol; 2013 Jul; 51(7):2409-10. PubMed ID: 23637297
[TBL] [Abstract][Full Text] [Related]
35. Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening.
Oštrbenk Valenčak A; Cuschieri K; Connor L; Zore A; Smrkolj Š; Poljak M
J Clin Virol; 2024 Feb; 170():105638. PubMed ID: 38183829
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the clinical performance of the cobas 4800 HPV test in patients referred for colposcopy.
White C; Keegan H; Pilkington L; Ruttle C; Kerr P; Sharp L; O'Toole S; Turner M; Prendiville W; D'Arcy T; Fitzpatrick M; Lenehan P; Flannelly G; O'Leary JJ; Martin CM
J Clin Microbiol; 2013 Oct; 51(10):3415-7. PubMed ID: 23903550
[TBL] [Abstract][Full Text] [Related]
37. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
38. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
